Research graph
References from Treatment of Breast Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Breast cancer statistics 2024
2024 · External reference
Global patterns and trends in breast cancer incidence and mortality across 185 countries
10.1038/s41591-025-03502-3 · 2025 · External reference
Impact of Covid-19 on breast cancer screening
10.31557/apjcp.2024.25.8.2703 · 2024 · External reference
Understanding susceptibility to breast cancer: from risk factors to prevention strategies
10.3390/ijms26072993 · 2025 · External reference
Updates in the evaluation and management of breast cancer
10.1016/j.mayocp.2018.03.025 · 2018 · External reference
Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology Guideline
10.1200/jco.23.02225 · 2024 · External reference
WHO Classification of Tumours Editorial Board. The 2019 World Health Organization classification of tumours of the breast
10.1111/his.14091 · 2020 · External reference
Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial
10.1200/jco.2015.60.8133 · 2015 · External reference
Molecular markers in the diagnosis and staging of breast cancer
10.1053/srao.2002.35249 · 2002 · External reference
Standard-of-care treatment for HER2+ metastatic breast cancer and emerging therapeutic options
10.1177/11782234241234418 · 2024 · External reference
Advances in systemic therapies for triple negative breast cancer
10.1136/bmj-2022-071674 · 2023 · External reference
New treatment approaches for triple-negative breast cancer
10.1200/edbk-25-481154 · 2025 · External reference
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
10.1016/j.annonc.2023.05.008 · 2023 · External reference
Implications for breast cancer restaging based on the 8th edition AJCC Staging Manual
10.1097/sla.0000000000003071 · 2020 · External reference
Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group
10.1093/jnci/djaa201 · 2021 · External reference
Molecular portraits of human breast tumours
10.1038/35021093 · 2000 · External reference
Clinical implications of the intrinsic molecular subtypes of breast cancer
10.1016/j.breast.2015.07.008 · 2015 · External reference
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer
10.1056/nejm199511303332203 · 1995 · External reference
Contralateral prophylactic mastectomy: challenging considerations for the surgeon
10.1245/s10434-015-4758-y · 2015 · External reference
Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks
10.1245/s10434-016-5443-5 · 2016 · External reference
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
10.1016/s1470-2045(10)70207-2 · 2010 · External reference
Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial
10.1001/jamaoncol.2023.3759 · 2023 · External reference
Axillary surgery in breast cancer — primary results of the INSEMA trial
10.1056/nejmoa2412063 · 2025 · External reference
Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)
10.1186/s12885-017-3443-x · 2017 · External reference
No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial
10.1186/s12885-022-09273-1 · 2022 · External reference
A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy
10.1097/sla.0000000000002313 · 2018 · External reference
Selective elimination of breast surgery for invasive breast cancer: a nonrandomized clinical trial
10.1001/jamaoncol.2025.0207 · 2025 · External reference
Breast cancer cryoablation fundamentals past and present: technique optimization and imaging pearls
10.1016/j.acra.2023.05.019 · 2023 · External reference
Cryoablation without excision for early-stage breast cancer: ICE3 trial 5-year follow-up on ipsilateral breast tumor recurrence
10.1245/s10434-024-16181-0 · 2024 · External reference
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials
10.1016/s0140-6736(11)61629-2 · 2011 · External reference
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
10.1016/s0140-6736(14)60488-8 · 2014 · External reference
Breast-conserving surgery with or without irradiation in early breast cancer
10.1056/nejmoa2207586 · 2023 · External reference
Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial
10.1200/jco.20.00650 · 2020 · External reference
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial
10.1016/s1470-2045(24)00661-2 · 2025 · External reference
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
10.1016/s0140-6736(20)30932-6 · 2020 · External reference
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial
10.1016/s0140-6736(23)00619-0 · 2023 · External reference
Omitting regional nodal irradiation after response to neoadjuvant chemotherapy
10.1056/nejmoa2414859 · 2025 · External reference
Ten-year survival after postmastectomy chest-wall irradiation in breast cancer
10.1056/nejmoa2412225 · 2025 · External reference
A randomized trial of hypofractionated post-mastectomy radiation therapy (PMRT) in women with breast reconstruction (RT CHARM, Alliance A221505)
10.1016/j.ijrobp.2024.07.002 · 2024 · External reference
Hypofractionated vs conventionally fractionated postmastectomy radiation after implant-based reconstruction: a randomized clinical trial
10.1001/jamaoncol.2024.2652 · 2024 · External reference
Comparison of deep inspiration breath hold versus free breathing in radiotherapy for left sided breast cancer
2022 · External reference
A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis
10.1200/jco.2007.15.2488 · 2008 · External reference
Assessment of proton beam therapy use among patients with newly diagnosed cancer in the US, 2004-2018
2022 · External reference
RadComp (Radiotherapy Comparative Effectiveness Consortium). Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol
10.1136/bmjopen-2018-025556 · 2019 · External reference
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial
10.1016/s1470-2045(25)00194-9 · 2025 · External reference
Financial toxicity of partial versus whole breast irradiation: a systematic review
2025 · External reference
Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer
10.1056/nejmoa2302344 · 2023 · External reference
Long-term results of hypofractionated radiation therapy for breast cancer
10.1056/nejmoa0906260 · 2010 · External reference
START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
10.1016/s1470-2045(13)70386-3 · 2013 · External reference
Breast Cancer Expert Panel of the German Society of Radiation Oncology DEGRO. DEGRO statement on the FAST-Forward trial: 10-year data of ultrahypofractionated radiation therapy for breast cancer
10.1007/s00066-025-02481-1 · 2026 · External reference
Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial
10.1007/s00066-020-01730-9 · 2021 · External reference
Hypofractionated whole-breast radiation therapy with simultaneous integrated boost after breast-conserving surgery: preliminary real-life experience of the Radiation Therapy Oncology Group 1005 trial
10.1093/bjr/tqaf157 · 2025 · External reference
Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis
10.1001/jamaoncol.2016.1897 · 2016 · External reference
Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline
10.1200/jco.20.03399 · 2021 · External reference
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update
10.1200/jop.18.00617 · 2019 · External reference
Tamoxifen in the treatment of breast cancer
10.1056/nejm199811263392207 · 1998 · External reference
Tamoxifen for early breast cancer: an overview of the randomised trials
10.1016/s0140-6736(97)11423-4 · 1998 · External reference
Symptoms associated with tamoxifen treatment in postmenopausal women
10.1001/archinte.1991.00400090120021 · 1991 · External reference
Unresolved reference
2019 · External reference
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
10.1016/s0140-6736(15)61074-1 · 2015 · External reference
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
10.6004/jnccn.2023.0031 · 2023 · External reference
Tailoring adjuvant endocrine therapy for premenopausal breast cancer
10.1056/nejmoa1803164 · 2018 · External reference
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials
10.1200/jco.22.01064 · 2023 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2022 · External reference
Treatment with adjuvant abemaciclib plus endocrine therapy in patients with high-risk early breast cancer who received neoadjuvant chemotherapy: a prespecified analysis of the monarchE randomized clinical trial
10.1001/jamaoncol.2022.1488 · 2022 · External reference
Ribociclib plus endocrine therapy in early breast cancer
10.1056/nejmoa2305488 · 2024 · External reference
monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
10.1016/j.annonc.2022.03.006 · 2022 · External reference
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
10.1007/s10549-020-06029-y · 2021 · External reference
Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline
10.1200/jco.2016.70.7257 · 2017 · External reference
CYP2D6 genotype and outcome in tamoxifen treated early breast cancer
10.2340/1651-226x.2025.43208 · 2025 · External reference
Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study
10.1200/jco.18.00307 · 2019 · External reference
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy
10.1016/s0140-6736(25)01013-x · 2025 · External reference
Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
10.1016/s0140-6736(12)61963-1 · 2013 · External reference
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial
10.1093/annonc/mdz289 · 2019 · External reference
Austrian Breast and Colorectal Cancer Study Group. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer
10.1056/nejmoa2104162 · 2021 · External reference
Selection of patients with early-stage breast cancer for extended endocrine therapy: a secondary analysis of the IDEAL randomized clinical trial
2024 · External reference
Breast cancer in men
10.1056/nejmra1707939 · 2018 · External reference
Management of male breast cancer: ASCO guideline
10.1200/jco.19.03120 · 2020 · External reference
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
10.1056/nejmoa1406281 · 2015 · External reference
Trastuzumab emtansine for residual invasive HER2-positive breast cancer
10.1056/nejmoa1814017 · 2019 · External reference
Trastuzumab deruxtecan in residual HER2-positive early breast cancer
10.1056/nejmoa2514661 · 2026 · External reference
Adjuvant capecitabine for breast cancer after preoperative chemotherapy
10.1056/nejmoa1612645 · 2017 · External reference
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
10.1016/j.annonc.2022.09.159 · 2022 · External reference
Pembrolizumab for early triple-negative breast cancer
10.1056/nejmoa1910549 · 2020 · External reference
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18
10.1093/oxfordjournals.jncimonographs.a003469 · 2001 · External reference
NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel
1997 · External reference
Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902
10.1007/s10549-008-0050-1 · 2009 · External reference
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
10.1200/jco.2007.10.6823 · 2007 · External reference
Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis
10.1158/0008-5472.can-20-1792 · 2020 · External reference
Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer
10.1200/jco.22.02241 · 2023 · External reference
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial
10.1001/jama.2013.278932 · 2013 · External reference
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
10.1016/s1470-2045(13)70166-9 · 2013 · External reference
Neoadjuvant treatment for HER2-positive breast cancer
10.21037/cco-20-123 · 2020 · External reference
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
10.1093/annonc/mdt182 · 2013 · External reference
Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
10.1056/nejmoa1703643 · 2017 · External reference
Survival with trastuzumab emtansine in residual HER2-positive breast cancer
10.1056/nejmoa2406070 · 2025 · External reference
Unresolved reference
2025 · External reference
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
10.1016/j.annonc.2025.10.019 · 2026 · External reference
Overall survival with pembrolizumab in early-stage triple-negative breast cancer
10.1056/nejmoa2409932 · 2024 · External reference
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
10.1016/j.annonc.2024.02.002 · 2024 · External reference
Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: when, why and what?
10.1016/j.critrevonc.2021.103280 · 2021 · External reference
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial
10.1001/jamaoncol.2019.6650 · 2020 · External reference
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial
10.1038/s41591-024-03415-7 · 2025 · External reference
Breast cancer treatment: a review
10.1001/jama.2018.19323 · 2019 · External reference
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
10.1056/nejm200103153441101 · 2001 · External reference
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
10.1016/s1470-2045(19)30863-0 · 2020 · External reference
Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial
10.1200/jco.21.02937 · 2023 · External reference
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
10.1056/nejmoa064320 · 2006 · External reference
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA trial
10.1200/jco.20.00147 · 2020 · External reference
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
10.1056/nejmoa1914609 · 2020 · External reference
Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial
10.1200/jco.20.00775 · 2020 · External reference
Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial
10.1001/jamaoncol.2022.5610 · 2023 · External reference
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
10.1016/s1470-2045(20)30702-6 · 2021 · External reference
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
10.1136/bmj-2023-076065 · 2023 · External reference
Trastuzumab emtansine for HER2-positive advanced breast cancer
10.1056/nejmoa1209124 · 2012 · External reference
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
10.1056/nejmoa1914510 · 2020 · External reference
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
10.1038/s41591-024-03021-7 · 2024 · External reference
Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer
10.1056/nejmoa2508668 · 2026 · External reference
Cyclin-dependent kinase 4/6 inhibitors for treatment of hormone receptor-positive, ERBB2-negative breast cancer: a review
10.1001/jamaoncol.2023.2000 · 2023 · External reference
Overall survival with ribociclib plus letrozole in advanced breast cancer
10.1056/nejmoa2114663 · 2022 · External reference
Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer
10.1056/nejmoa2404625 · 2024 · External reference
Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial
10.1200/jco.22.02392 · 2023 · External reference
Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4/6 inhibition: results from the phase III postMONARCH Trial
10.1200/jco-24-02086 · 2025 · External reference
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges
10.1038/s41416-021-01564-x · 2022 · External reference
Phosphoinositide 3-kinase (PI3K) inhibitors and breast cancer: an overview of current achievements
10.3390/cancers15051416 · 2023 · External reference
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
10.1056/nejmoa1813904 · 2019 · External reference
Capivasertib in hormone receptor-positive advanced breast cancer
10.1056/nejmoa2214131 · 2023 · External reference
Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial
10.1200/jco.22.00338 · 2022 · External reference
Imlunestrant with or without abemaciclib in advanced breast cancer
10.1056/nejmoa2410858 · 2025 · External reference
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
10.1093/annonc/mdu456 · 2014 · External reference
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation
10.1056/nejmoa1802905 · 2018 · External reference
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation
10.1056/nejmoa1706450 · 2017 · External reference
Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies
10.1007/s00109-021-02136-5 · 2021 · External reference
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
10.1016/s0140-6736(23)01245-x · 2023 · External reference
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01
10.1200/jco.24.00920 · 2025 · External reference
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
10.1056/nejmoa2203690 · 2022 · External reference
Survival following CDK4/6 inhibitor therapy for hormone receptor-positive, ERBB2-negative metastatic breast cancer
10.1001/jamanetworkopen.2024.61067 · 2025 · External reference
Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer
10.1056/nejmoa2202809 · 2022 · External reference
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
10.1016/s0140-6736(20)32531-9 · 2020 · External reference
Sacituzumab govitecan in metastatic triple-negative breast cancer
10.1056/nejmoa2028485 · 2021 · External reference
OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
10.1093/annonc/mdz012 · 2019 · External reference
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
10.1016/j.ejca.2023.01.031 · 2023 · External reference
Unresolved reference
2025 · External reference
HER2CLIMB-05: a phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer
2025 · External reference
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
10.1016/s0140-6736(22)02420-5 · 2023 · External reference
Unresolved reference
2025 · External reference
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis
10.1093/neuonc/noaa285 · 2021 · External reference
Palbociclib and letrozole in advanced breast cancer
10.1056/nejmoa1607303 · 2016 · External reference
MONARCH 3: abemaciclib as initial therapy for advanced breast cancer
10.1200/jco.2017.75.6155 · 2017 · External reference
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3
10.1016/j.annonc.2024.04.013 · 2024 · External reference
MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy
10.1200/jco.2017.73.7585 · 2017 · External reference
The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial
10.1001/jamaoncol.2019.4782 · 2020 · External reference
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
10.1093/annonc/mdy155 · 2018 · External reference
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
10.1016/j.annonc.2021.05.353 · 2021 · External reference
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
10.1016/s1470-2045(18)30292-4 · 2018 · External reference
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1
10.1016/j.annonc.2020.11.011 · 2021 · External reference
Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer
10.1056/nejmoa2501796 · 2025 · External reference
Overall survival with palbociclib and fulvestrant in advanced breast cancer
10.1056/nejmoa1810527 · 2018 · External reference
Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study
2025 · External reference
Unresolved reference
External reference
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
10.1016/j.annonc.2026.03.008 · 2026 · External reference
International Immuno-Oncology Biomarker Working Group. Tumor-infiltrating lymphocytes in triple-negative breast cancer
10.1001/jama.2024.3056 · 2024 · External reference
Clinical validity and clinical utility of Ki67 in early breast cancer
10.1177/17588359221122725 · 2022 · External reference
Use of ctDNA in early breast cancer: analytical validity and clinical potential
10.1038/s41523-024-00653-3 · 2024 · External reference
